Stereochemistry | ACHIRAL |
Molecular Formula | C18H21N5O3 |
Molecular Weight | 355.391 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=CC=C(NC(=O)CN2C=NC3=C2C(=O)N(C)C(=O)N3C)C=C1
InChI
InChIKey=HEQDZPHDVAOBLN-UHFFFAOYSA-N
InChI=1S/C18H21N5O3/c1-11(2)12-5-7-13(8-6-12)20-14(24)9-23-10-19-16-15(23)17(25)22(4)18(26)21(16)3/h5-8,10-11H,9H2,1-4H3,(H,20,24)
Molecular Formula | C18H21N5O3 |
Molecular Weight | 355.391 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
HC-030031 is a substituted theophylline derivative. Potent and selective TRPA1 inhibitor. HC-030031 inhibits human and rat TRPA1 with IC50 of 6.2 and 7.6 uM, respectively. It is selective against several TRP channels (IC50 >10 or 20 uM). HC-030031 can block both inward and outward currents elicited by AITC or formalin rapidly and reversibly and also blocks the activation of TRPA1 by N-methylmaleimide and by electrophillic prostaglandins. It does not block currents mediated by TRPV1, TRPV3, TRPV4 hERG, or NaV1.2 channels. HC-030031 exhibited efficacy in CFA, SNL, and other pain models. HC-030031
was shown to attenuate cold hyperalgesia in CFA (inflammatory),
spared never injury (SNI, neuropathic), and paclitaxelmediated
cold hyperalgesia. Also HC-030031 was found to decrease
heat hyperalgesia in the paclitaxel model of
chemotherapy-induced neuropathic pain.In an ovalbumin-induced mouse asthma
model, gene KO and treatment with HC-030031 reduced the
induction of cytokines, chemokines, neurotransmitters, as
well as leukocyte infiltration and airway hyperactivity. Furthermore, HC-030031
and genetic deletion of mast cells attenuated itch-scratching
behaviors. In oxazolone-induced contact dermatitis models,
TRPA1 KO and HC-030031 decreased pro-inflammatory cytokines,
T cell infiltration, dermatitis score, and edema, indicating
that TRPA1 may play a central role in inflammation and
pruritus.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
Mice: HC-030031 was injected i.c.v. (30 nmol in 2 uL, 5 min i.c.v. min before the behavioural test or administered p.o. at doses of 30, 100
and 300 mg/kg, by employing a gavage needle, in a volume
of 10 mL/kg, 90 (p.o.) min before the behavioural test
Route of Administration:
Other